Financials

	2022	2023
Net sales	54.13M 47.46M 44.09M 40.49M 76.26M 5.23B 77.47M 524M 205M 2.55B 203M 199M 8.83B	80.75M 70.8M 65.78M 60.41M 114M 7.8B 116M 782M 306M 3.81B 303M 297M 13.17B
Net income	-18.11M -15.87M -14.75M -13.55M -25.51M -1.75B -25.91M -175M -68.62M -854M -67.96M -66.51M -2.95B	-20.13M -17.65M -16.4M -15.06M -28.36M -1.94B -28.81M -195M -76.29M -950M -75.56M -73.94M -3.28B
Net Debt	42.09M 36.9M 34.29M 31.49M 59.3M 4.06B 60.24M 408M 160M 1.99B 158M 155M 6.87B	55.34M 48.52M 45.08M 41.4M 77.96M 5.34B 79.2M 536M 210M 2.61B 208M 203M 9.03B

* Estimated data More financial data

Company Profile

Alimera Sciences, Inc. is a global pharmaceutical company. The Company is focused on helping patients, physicians and partners concerned with retinal health and maintaining better vision longer.

Employees

157

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 00:00:00 14/09/2024 +04			5-day change	1st Jan Change
5.540 ^USD	-0.18%		-.--%	-

16/09/24	ANI Pharmaceuticals Completes Purchase of Alimera Sciences, Sees 'Substantially Higher' Earnings After Deal	MT
16/09/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from NASDAQ Composite Index	CI

Market Cap	301M 264M 245M 225M 424M 29.09B 431M 2.92B 1.14B 14.22B 1.13B 1.11B 49.14B	P/E 2022	-1.05x	P/E 2023	-5.16x
Enterprise Value	357M 313M 290M 267M 502M 34.43B 510M 3.46B 1.35B 16.83B 1.34B 1.31B 58.17B	EV / Sales 2022	1.13x	EV / Sales 2023	3.49x
Free-Float	94.65%	Yield 2022 *	-	Yield 2023	-

16/09/24	ANI Pharmaceuticals Completes Purchase of Alimera Sciences, Sees 'Substantially Higher' Earnings After Deal	MT
16/09/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from NASDAQ Composite Index	CI
16/09/24	ANI Pharmaceuticals, Inc. completed the acquisition of Alimera Sciences, Inc. from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.	CI
11/09/24	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Looming CPI Data Likely to Provide Rate-Cut Clues	MT
11/09/24	ANI Pharmaceuticals, Alimera Sciences to Close Merger Next Week	MT
10/09/24	Alimera Sciences Sues ANI Pharmaceuticals for Delays in Merger Close	MT
10/09/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from S&P TMI Index	CI
06/08/24	Alimera Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
17/07/24	Processa Pharmaceuticals Appoints Russell Skibsted as CFO	MT
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell Small Cap Comp Value Index	CI
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell Small Cap Completeness Index	CI
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell 2000 Index	CI
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell 3000E Index	CI

25/06/24	Maxim Downgrades Alimera Sciences to Hold From Buy	MT
25/06/24	Alliance Global Partners Downgrades Alimera Sciences to Neutral From Buy, Adjusts Price Target to $5.50 From $8	MT
25/06/24	Craig-Hallum Downgrades Alimera Sciences to Hold From Buy, Price Target is $5.50	MT
25/06/24	HC Wainwright Downgrades Alimera Sciences to Neutral From Buy, Price Target is $6	MT
25/03/24	Maxim Initiates Alimera Sciences at Buy Rating With $10 Price Target	MT

Alimera Sciences, Inc. Stock

Stocks

ALIM

US0162592028

Pharmaceuticals

Valuation: Alimera Sciences, Inc.

Latest news : Alimera Sciences, Inc.

Analysts' recommendations: Alimera Sciences, Inc.

Press Releases: Alimera Sciences, Inc.

News in other languages: Alimera Sciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Alimera Sciences, Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Income Statement and Estimates

16/09/24	ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences	AQ
11/09/24	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger	BU
11/09/24	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger	AQ
10/09/24	ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences	AQ
10/09/24	Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement	BU

Manager	Title	Age	Since
Elliot Maltz DFI	Director of Finance/CFO	41	02/01/2024
Jason Werner COO	Chief Operating Officer	48	02/10/2023
Laura Cegala HRO	Human Resources Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/09/24	Philip Ashman	Issuer sale	Executive/Senior Manager	1,192,074	2.1920%
16/09/24	Todd Wood	Issuer sale	President of U.S. Operations	375,000	0.6895%
16/09/24	Caligan Partners LP	Others	Company	17,635,155	32.4270%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALIMERA SCIENCES, INC.	-0.18%	-.--%	-.--%	+57.83%	287M
REGENERON PHARMACEUTICALS, INC.	-3.56%	-0.75%	+19.37%	-11.36%	68.69B
UCB	-0.25%	+4.65%	+40.39%	+196.63%	52.97B
SAMSUNG BIOLOGICS CO.,LTD.	-1.65%	+37.20%	+37.20%	+37.20%	43.61B
CSL LIMITED	-2.83%	-4.08%	-53.81%	-55.84%	40.75B
BIOGEN INC.	-2.67%	+3.02%	+61.18%	-28.55%	29.99B
MODERNA, INC.	-2.67%	-13.89%	+87.50%	-54.07%	23.67B
INCYTE CORPORATION	-1.36%	+0.79%	+71.85%	+80.50%	23.45B
INNOVENT BIOLOGICS, INC.	+0.11%	+2.44%	+4.06%	+181.25%	20.46B
SWEDISH ORPHAN BIOVITRUM AB	-0.39%	+2.03%	+72.19%	+122.26%	16.66B
Average	-1.25%	+0.60%	+33.99%	+52.59%	32.05B
Weighted average by Cap.	-1.73%	+1.22%	+30.50%	+45.22%

3 years	2.61	5.65
5 years	1.3	9.79
10 years	0	36